ALPHAMAB-B: JSKN003 has been granted FTD by the U.S. FDA for the treatment of PROC
I'm PortAI, I can summarize articles.
ALPHAMAB-B announced that its drug JSKN003 has received Fast Track Designation (FTD) from the U.S. FDA for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. This milestone marks the progress of JSKN003's global development. In addition, JSKN003 has also received approval for Phase II clinical trials and has been granted Breakthrough Therapy Designation for PROC and colorectal cancer. The Phase III clinical trial of the drug is progressing smoothly in China
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments